Mouse Anti-Hsp90 Monoclonal Antibody (CBP2504)

Product Overview

Description

Hsp90 is one of the most abundant molecular chaperones. It modulates the stability and transport of a diverse set of critical factors, which include regulatory, metabolic, organizational, and signaling proteins. There are two major isoforms: α and β. In humans, the Hsp90β isoform is constitutively expressed, whereas the Hsp90α isoform is expressed under stress conditions. The Hsp90 dimer acts in concert with other chaperones and is regulated by a number of co-chaperones/accessory proteins. The upregulation of Hsp90 is associated with tumor progression, the invasion and formation of metastases, and the development of drug resistance. Therefore, Hsp90 has emerged as an important target for cancer treatment.

Species Reactivity

Human; Rat

Clonality

Monoclonal

Host Species

Mouse

Isotype

IgG2b, κ

Clone Number

CBP2504

Applications

WB; IP

Application Notes

WB (0.125-1.0 µg/mL); IP (10-30 μg/mL)

Relevant Diseases

Brain Tumors; Alzheimer's Disease; Parkinson's Disease; Neurocutaneous Syndromes

Research Areas

Neuroinflammation

Conjugation

Unconjugated

Product Properties

Form

Liquid

Formulation

PBS, pH 7.2, containing 0.09% sodium azide

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Purity

>95%, as determined by Coomassie stained SDS-PAGE.

Shipping

The product is shipped at 4°C. Upon receipt, store it immediately at the recommended temperature.

Storage

The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.

Handling Advice

Upon receipt, the antibody solution should be stored undiluted at -20°C, and protected from prolonged exposure to light.

Research Use Only

For research use only, not for diagnostic or therapeutic use.

Target

HSP90 alpha

Official Name

Hsp90

Full Name

heat shock protein 90

Alternative Names

HATPase

Gene ID

3326(Human); 15516(Mouse); 301252(Rat)

Uniprot ID

P08238(Human); P11499(Mouse); P34058(Rat)

References

1. Barrott JJ, et al. 2013. FEBS J. 280:1381.
2. Gorska M, et al. 2012. Front. Biosci. (Landmark Ed) 17:2269.
3. Barginear MF, et al. 2008. Curr. Cancer Drug Targets 8:522.
4. Arya R, et al. 2007. J. Biosci. 32:595.
5. Neckers L, et al. 2003. Curr. Opin. Oncol. 15:419.
6. Nemoto T, et al. 1997. J. Biol. Chem. 272:26179.

Publications